Relmada Therapeutics, Inc.
RLMD
$0.627
$0.0172.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.60M | 34.30M | 37.72M | 41.72M | 42.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.52M | 79.12M | 83.89M | 91.64M | 91.33M |
| Operating Income | -70.52M | -79.12M | -83.89M | -91.64M | -91.33M |
| Income Before Tax | -67.81M | -75.71M | -79.98M | -86.49M | -86.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.81 | -75.71 | -79.98 | -86.49 | -86.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.81M | -75.71M | -79.98M | -86.49M | -86.76M |
| EBIT | -70.52M | -79.12M | -83.89M | -91.64M | -91.33M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.21 | -2.50 | -2.65 | -2.87 | -2.88 |
| Normalized Basic EPS | -1.39 | -1.58 | -1.67 | -1.81 | -1.80 |
| EPS Diluted | -2.21 | -2.50 | -2.65 | -2.87 | -2.88 |
| Normalized Diluted EPS | -1.39 | -1.58 | -1.67 | -1.81 | -1.80 |
| Average Basic Shares Outstanding | 123.95M | 120.93M | 120.65M | 120.58M | 120.50M |
| Average Diluted Shares Outstanding | 123.95M | 120.93M | 120.65M | 120.58M | 120.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |